Founder and CSO, Hatchtech
| Role | Organisation | Sources |
|---|---|---|
| Deputy Director (former) | Centre for Animal Biotechnology | OneVentures portfolio |
| Founder and CSO (former) | Hatchtech | GBS Ventures, OneVentures portfolio |
| Inventor (former) | University of Melbourne | GBS Ventures |
Stories naming Professor Vern Bowles. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
GBS Ventures marks its fourth FDA drug approval as Hatchtech's head lice treatment Xeglyze clears the regulator, recalling earlier wins behind Picato, Synribo and Aridol with Australian biotech firms.